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Antiphospholipid antibodies may be associated
with venous thromboembolism and/or arterial
thromboses or miscarriages; their heterogeneity
complicates the laboratory diagnosis. For a long
time, they were believed to be directed against
anionic phospholipids. More recently, it has been
demonstrated that these antibodies are directed at
plasma proteins bound most of the time to a phos-
pholipid surface (anionic phospholipids). Several
cardiolipin antibodies and lupus anticoagulant be-
long to this variety of antibodies. An extremely rich
literature is available on this subject. 1-4
The laboratory diagnosis of the so-called "Anti-
phospholipid Syndrome," is relatively difficult be-
cause of the heterogeneity of the antibodies, the
large number of laboratory tests which have been
advocated, and their standardization which has to
be improved for many of them. z
Laboratory diagnosis is usually considered in pa-
tients with unexplained venous and/or arterial
thromboses, recurrent miscarriages, and thrombo-
cytopenia,s,6 However, in several subjects the de-
tection of a lupus or lupus-like circulating antico-
agulant is made during preoperative laboratory
testing, particularly in a child before tonsillectomy.
The clinical significance of these latter antibodies
is different than that of the previous group of
symptomatic patients. The measurement of anti-
cardiolipin (aCL) antibodies should be performed
in parallel in every patient with a suspected anti-
phospholipid syndrome. Many recommendations
concerning the preanalytical variables, especially
regarding the risk of platelet contamination which
may suppress the anticoagulant activity, must be
taken into account, z,4,7 The laboratory diagnosis of
a lupus anticoagulant (LAC) relies on a four-step
procedure for blood examination.
1. In the first step, the prolongation of the partial
thromboplastin time with a ratio patient/control su-
perior to 1:20 is detected. Several reagents are
available, and the selection of a sensitive test is
crucial. 7
2. In the second step, it is essential to demonstrate
that the addition of patient’s plasma to a control
plasma prolongs the activated partial thromboplas-
tin time of the latter. In few cases the clotting time
is longer than that of the patient. The measure-
ment of the APTT of the control plasma, the pa-
tient’s plasma, and their mixture (one volume of
each) leads to the calculation of the Rosner index,
the normal values of which are lower than 13 or 15,
according to different investigators.
3. In the third step, a laboratory test is selected in
order to demonstrate the antiphospholipid depen-
dence of the LAC. Several reagents have been pro-
posed: phospholipids present in a platelet prepara-
tion, hexagonal phospholipids, dilute tissue throm-
boplastin reagent, or dilute Russel viper venom.
Their respective sensitivity and specificity are mat-
ters of debate. A new screening test using Textarin
venom seems to be very sensitive to LAC.
4. In the fourth step, a confirmatory test can be
useful in order to demonstrate that a deficiency in
factor VIII or factor II is not associated with LAC or
in very rare cases falsely diagnosed as a lupus an-
ticoagulant. This differential diagnosis is essential
since inhibitors specifically directed at factor VIII
or factor II are associated with severe hemorrhages
in contrast to the LAC.
The differential diagnosis of LAC and factor
VIII antibody relies on the measurement of plasma
factor VIII concentration in increasing dilutions of
the patient plasma (1 to 10, to 20, and to 40). In
LAC the level of factor VIII increases when greater
dilutions are used. In the presence of anti-factor
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VIII, the factor VIII concentration remains con-
stant when different plasma dilutions are used.
In patients with recurrent fetal losses, the labo-
ratory diagnosis of LAC should be performed with
very sensitive reagents and anticardiolipin antibod-
ies measurement should be done in parallel. A solid
phase ELISA method is used to measure aCL an-
tibodies. IgG and IgM antibodies directed against
phospholipids binding plasma proteins, 132 glyco-
protein or prothrombin essentially or directed at
these glycoproteins themselves have been ob-
served during the phospholipid antibody syn-
drome,s,9 it is important to demonstrate that they
persist at two consecutive tests with a 2 to 3 month
interval.
Other glycoproteins associated with phospholip-
ids are annexin V, high and low moleeular weight
kininogen, protein C, and protein S.
Since 132 GP1 is a required cofactor for anticar-
diolipin antibody binding in the ELISA,9 four hy-
potheses have been proposed to explain the speci-
ficity of aCL:
1. CL is directly recognized by aCL.
2. 132 GP1-CL complex is the structure recognized
by aCL.
3. [32 GP1 is the target antigen for aCL but the
epitope is cryptic in the absence of CL.
4. The actual epitope for aCL appears on the na-
tive structure of [32 GP1.
Alloantibodies are usually directed at phospho-
lipids and give a negative reaction for antibodies
directed to 1321 GP 1. They are observed in patients
with syphilis or with a viral infection including
VIH.1 In contrast, autoantibodies that are encoun-
tered in patients with venous and/or arterial throm-
bosis and/or recurrent fetal losses are frequently
directed against 132 GP1 associated in some cases
with cardiolipins. Very recently a relationship be-
tween the presence of antibodies of the IgM sub-
type directed at 132 GP1 and recurrent fetal losses
has been reported.6
Thus, important progress in the classification of
antiphospholipid antibodies and their laboratory
detection has been achieved. This will lead to a
better understanding of the clinical relevance of
the presence in blood of these heterogeneous an-
tibodies.8 In patients with recurrent fetal losses it
will be interesting to investigate in further studies
whether IgM antibodies directed at 132 GP1 are
related to the pathogenesis of recurrent abortions.
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